Wegovy pill passes 3 million prescriptions in five months

Novo Nordisk announced on June 7 that Wegovy (semaglutide) tablets 25 mg have passed 3 million US prescriptions in just over five months since launching January 5, 2026 — a pace the company describes as roughly one prescription filled every five seconds ^[1]. Novo calls it "one of the strongest US pharmaceutical launches by volume on record" ^[1].

The company says the pill hit its first million prescriptions 12 weeks after reaching pharmacies and online providers (the week of Jan. 5 through the week of March 23), then added two million more in just 10 weeks (the week of March 23 through the week of June 1) ^[1]. The announcement landed during the American Diabetes Association's 2026 Scientific Sessions in New Orleans, held June 5-8 ^[1].

Who is filling these prescriptions

The number Novo highlighted most is 82%: that share of new-to-brand Wegovy pill starts so far in 2026 went to people with no other obesity or diabetes GLP-1 prescription in the prior 12 months, based on IQVIA data covering the weeks ending Jan. 9 through May 15 ^[1]. That lookback did not count compounded products ^[1]. Novo frames this as evidence the pill is expanding the market rather than pulling people off injections ^[1].

The prescription total itself comes from Novo's partner-reported paid claims between Jan. 5 and June 2, 2026 ^[1]. The "strongest launches on record" claim rests on IQVIA paid total prescriptions across more than 1,888 US branded launches (excluding vaccines) since 2013, measured at four months post-launch ^[1].

One caveat worth noting: analysts at Jefferies and Citi have said IQVIA prescription data may seriously underreport telehealth referrals, which can skew comparisons between products ^[2]. Novo's own 3 million figure is based on paid claims rather than IQVIA alone ^[1].

Price and access details

Novo launched the pill's starting 1.5 mg dose at $149 per month for people paying cash ^[2]. People with commercial insurance may pay as little as $25 per month through savings programs, subject to a maximum savings of $100 per month, with government beneficiaries excluded ^[1]. Starting July 1, 2026, the Medicare GLP-1 Bridge is set to give eligible Medicare beneficiaries with obesity access to Wegovy injection and tablets for a $50 monthly copay, with eligibility criteria determined by CMS ^[1]. Novo says the product is available through more than 70,000 US pharmacies, its NovoCare Pharmacy, and select telehealth providers ^[1].

For context on the competitive picture: Novo's pill launched several months before Eli Lilly's oral GLP-1, Foundayo (orforglipron), which reached the market in early April ^[2]. Novo reported $355 million in Wegovy pill sales in its first quarter on the market and narrowed its 2026 guidance to a 4% to 12% sales decline, from a previously forecast 5% to 13% decline ^[2].

Why it matters for patients

A pill version of semaglutide changes the practical shape of obesity treatment for people who did not want injections, and the 82% figure suggests many of those filling it are new to the drug class entirely ^[1]. Novo's US commercial lead, Ed Cinca, said roughly 120 million Americans would qualify for an anti-obesity medication and "such a small few" are receiving one ^[2].

High launch volume does not tell you how well a drug works for any individual, how long people stay on it, or what insurance will cover next year. Wegovy tablets carry the same labeled risks as other semaglutide products, including a boxed warning about thyroid C-cell tumors seen in rodents, plus warnings for pancreatitis, gallbladder problems, dehydration and kidney problems, and severe stomach problems ^[1]. The label says Wegovy should not be used with other semaglutide products or other GLP-1 medicines, and that it is not known whether the tablets are safe and effective in people under 18 ^[1]. Breastfeeding is not recommended during treatment with the tablets ^[1].

What happens next

• July 1, 2026: The Medicare GLP-1 Bridge $50 copay program is scheduled to begin for eligible beneficiaries ^[1].
• Second half of 2026: Novo says it is preparing the first Wegovy pill launches outside the US, including in the United Arab Emirates ^[1].

How much of the early volume converts into long-term refills is not yet known from these sources.